Literature DB >> 12079737

Chemotherapy of canine leishmaniosis.

Gad Baneth1, Susan E Shaw.   

Abstract

Visceral leishmaniosis is a widespread and potentially fatal disease of dogs and humans common in the Mediterranean region, the Middle East, and South America. Canine leishmaniosis is most frequently treated with the drugs meglumine antimoniate, allopurinol, amphotericin B, or a combination of meglumine antimoniate and allopurinol. Therapy with the currently used drugs often achieves temporary clinical improvement and changes in immunologic parameters with restoration of the ability to mount parasite-specific cell mediated responses and decrease in anti-leishmanial antibody titers. However, treatment usually does not prevent relapse of disease or eliminate parasite carriage. Due to the current lack of an ultimate and effective therapy for canine leishmaniosis, new drugs, delivery systems and treatment strategies are necessary to achieve a consistent parasitological cure in infected dogs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12079737     DOI: 10.1016/s0304-4017(02)00115-2

Source DB:  PubMed          Journal:  Vet Parasitol        ISSN: 0304-4017            Impact factor:   2.738


  40 in total

1.  Superoxide dismutase and Glutathione peroxidase in the blood of dogs with Leishmaniasis.

Authors:  D Britti; S Sconza; V M Morittu; D Santori; A Boari
Journal:  Vet Res Commun       Date:  2008-09       Impact factor: 2.459

2.  Immunogenicity of the P-8 amastigote antigen in the experimental model of canine visceral leishmaniasis.

Authors:  E Carrillo; S Ahmed; K Goldsmith-Pestana; J Nieto; Y Osorio; B Travi; J Moreno; D McMahon-Pratt
Journal:  Vaccine       Date:  2006-11-10       Impact factor: 3.641

3.  Infectivity to Phlebotomus perniciosus of dogs naturally parasitized with Leishmania infantum after different treatments.

Authors:  Guadalupe Miró; Rosa Gálvez; Cristeta Fraile; Miguel A Descalzo; Ricardo Molina
Journal:  Parasit Vectors       Date:  2011-04-13       Impact factor: 3.876

4.  Canine leishmaniasis: the key points for qPCR result interpretation.

Authors:  Verónica Martínez; Javier Quilez; Armand Sanchez; Xavier Roura; Olga Francino; Laura Altet
Journal:  Parasit Vectors       Date:  2011-04-13       Impact factor: 3.876

5.  Canine leishmaniosis: in vitro efficacy of miltefosine and marbofloxacin alone or in combination with allopurinol against clinical strains of Leishmania infantum.

Authors:  Anna Maria Farca; B Miniscalco; P Badino; R Odore; P Monticelli; A Trisciuoglio; E Ferroglio
Journal:  Parasitol Res       Date:  2012-01-05       Impact factor: 2.289

6.  Production and characterization of stable amphotericin-resistant amastigotes and promastigotes of Leishmania mexicana.

Authors:  Hamdan I Al-Mohammed; Michael L Chance; Paul A Bates
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

7.  Treatment of canine visceral leishmaniasis by the vaccine Leish-111f+MPL-SE.

Authors:  Joelma Trigo; Melissa Abbehusen; Eduardo M Netto; Maria Nakatani; Geraldo Pedral-Sampaio; Robson Silva de Jesus; Yasuyuki Goto; Jeffrey Guderian; Randall F Howard; Steven G Reed
Journal:  Vaccine       Date:  2010-03-04       Impact factor: 3.641

8.  Comparative study on the short term efficacy and adverse effects of miltefosine and meglumine antimoniate in dogs with natural leishmaniosis.

Authors:  Marta Mateo; Laurence Maynard; Claudia Vischer; Paolo Bianciardi; Guadalupe Miró
Journal:  Parasitol Res       Date:  2009-02-24       Impact factor: 2.289

9.  Distinct antigen recognition pattern during zoonotic visceral leishmaniasis in humans and dogs.

Authors:  Yasuyuki Goto; Randall F Howard; Ajay Bhatia; Joelma Trigo; Maria Nakatani; Eduardo M Netto; Steven G Reed
Journal:  Vet Parasitol       Date:  2008-11-05       Impact factor: 2.738

10.  First study on efficacy and tolerability of a new alkylphosphocholine molecule (oleylphosphocholine-OlPC) in the treatment of canine leishmaniosis due to Leishmania infantum.

Authors:  Leticia Hernández; Rosa Gálvez; Ana Montoya; Rocio Checa; Alba Bello; Tom Bosschaerts; Herwig Jansen; Cristina Rupérez; Anny Fortin; Guadalupe Miró
Journal:  Parasitol Res       Date:  2013-11-06       Impact factor: 2.289

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.